Candel Therapeutics, Inc.

Candel Therapeutics, Inc.verified

CADL

Price:

$5.19

Market Cap:

$166.52M

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The c...[Read more]

Industry

Biotechnology

IPO Date

2021-07-27

Stock Exchange

NASDAQ

Ticker

CADL

The Enterprise Value as of November 2024 (TTM) for Candel Therapeutics, Inc. (CADL) is 163.63M

According to Candel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 163.63M. This represents a change of 144.08% compared to the average of 67.04M of the last 4 quarters.

Candel Therapeutics, Inc. (CADL) Historical Enterprise Value (quarterly & annually)

How has CADL Enterprise Value performed in the past?

The mean historical Enterprise Value of Candel Therapeutics, Inc. over the last ten years is 109.14M. The current 163.63M Enterprise Value has changed 14.89% with respect to the historical average. Over the past ten years (40 quarters), CADL's Enterprise Value was at its highest in in the June 2024 quarter at 185.34M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

109.14M

Median

142.27M

Minimum

4.34M

Maximum

199.28M

Candel Therapeutics, Inc. (CADL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Candel Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 589.19%

Maximum Annual Enterprise Value = 199.28M

Minimum Annual Increase = -96.95%

Minimum Annual Enterprise Value = 4.34M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202329.88M589.19%
20224.34M-96.95%
2021142.27M-16.28%
2020169.93M-14.73%

Candel Therapeutics, Inc. (CADL) Average Enterprise Value

How has CADL Enterprise Value performed in the past?

The current Enterprise Value of Candel Therapeutics, Inc. (CADL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

58.83M

5-year avg

109.14M

10-year avg

109.14M

Candel Therapeutics, Inc. (CADL) Enterprise Value vs. Peers

How is CADL’s Enterprise Value compared to its peers?

Candel Therapeutics, Inc.’s Enterprise Value is greater than Aerovate Therapeutics, Inc. (48.13M), greater than Adagene Inc. (59.89M), less than Acrivon Therapeutics, Inc. Common Stock (201.19M), less than Rezolute, Inc. (236.08M), greater than AN2 Therapeutics, Inc. (5.61M), greater than Molecular Partners AG (57.62M), less than Mineralys Therapeutics, Inc. (599.97M), less than Pharvaris N.V. (837.18M), less than PepGen Inc. (174.94M), greater than PMV Pharmaceuticals, Inc. (48.39M), greater than Acurx Pharmaceuticals, Inc. (23.37M), greater than Monopar Therapeutics Inc. (82.46M), greater than Enochian Biosciences, Inc. (98.76M), greater than Indaptus Therapeutics, Inc. (4.86M), greater than Tempest Therapeutics, Inc. (14.36M), greater than Comera Life Sciences Holdings, Inc. (-1593200.00), greater than Forte Biosciences, Inc. (-3085005.00), greater than Bionomics Limited (-9192868.00), greater than OKYO Pharma Limited (38.48M), greater than Anebulo Pharmaceuticals, Inc. (45.92M), greater than Cingulate Inc. (11.61M),

Build a custom stock screener for Candel Therapeutics, Inc. (CADL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Candel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Candel Therapeutics, Inc. (CADL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Candel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Candel Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Candel Therapeutics, Inc. (CADL)?

What is the 3-year average Enterprise Value for Candel Therapeutics, Inc. (CADL)?

What is the 5-year average Enterprise Value for Candel Therapeutics, Inc. (CADL)?

How does the current Enterprise Value for Candel Therapeutics, Inc. (CADL) compare to its historical average?